RecruitingPhase 1Phase 2NCT05719714
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Sponsor
Northwestern University
Enrollment
60 participants
Start Date
Jan 16, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria4
- \>18 years of age
- eGFR 25-60 ml/min/1,73m2 (eGFR = estimated glomerular filtration rate)
- On stable doses of diuretics and/or angiotensin converting enzyme inhibitor or angiotensin receptor blocker
- Evidence of subclinical heart failure with preserved ejection fraction at their pre-exercise echocardiogram (defined as meeting 3/5 of the American Society of Echocardiography (ASE) criteria for diastolic dysfunction \[septal e'\<7 cm/wc, average E/e' ratio\>14, left atrial volume index \>34 mL/m2, and peak TR velocity \>2.8 m/sec\] or absolute left ventricular longitudinal strain \< 18%, left atrial reservoir strain (LARS) \< 25% on 2d speckle tracking echocardiography), lack of augmentation of LVLS or LARS during exercise, or peak VO2 Females: ≤ 18 mL/kg/min, peak VO2 Males: ≤ 20 mL/kg/min on cardiopulmonary exercise testing.
Exclusion Criteria19
- presence or history of diabetes
- coronary revascularization within the last 6 months
- hemodynamically significant valvular disease
- significant lung disease requiring home oxygen
- angina (chest pain)
- non-revascularized myocardial ischemia
- systolic BP \<100 or \>180 mmHg
- pregnancy
- clinical heart failure symptoms
- history of systemic disease processes that can cause HFpEF such as amyloidosis or sarcoidosis
- any musculoskeletal or chronic condition that will interfere with completion of cardiac testing
- active cancer
- immunosuppressive therapy
- baseline or pre-exercise echocardiogram demonstrates a reduced ejection fraction \< 50%
- currently on sodium glucose cotransporter 2 inhibitor (SGLT2i) therapy
- Hypersensitivity to a SGLT2i
- Pre-existing liver disease
- ALT/AST\> 3x normal (ALT = alanine aminotransferase AST = aspartate aminotransferase)
- history of recurrent urinary tract infections (in the opinion of the investigator) or a urinary tract infection in the last 3 months
Interventions
DRUGDapagliflozin 10 MG [Farxiga]
10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05719714
Related Trials
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
NCT0659339212 locations
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location